Compare AMCX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | STTK |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.2M | 275.9M |
| IPO Year | 2011 | 2020 |
| Metric | AMCX | STTK |
|---|---|---|
| Price | $7.59 | $4.04 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $7.00 | $6.20 |
| AVG Volume (30 Days) | ★ 503.9K | 375.1K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | 27.32 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,311,801,000.00 | $5,721,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.53 | ★ N/A |
| Revenue Growth | N/A | ★ 245.26 |
| 52 Week Low | $5.41 | $0.69 |
| 52 Week High | $10.28 | $4.89 |
| Indicator | AMCX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 50.83 |
| Support Level | $6.96 | $3.52 |
| Resistance Level | $8.23 | $4.23 |
| Average True Range (ATR) | 0.50 | 0.30 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 28.25 | 56.90 |
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.